Noble Capital Starts Tonix Pharma (TNXP) at Outperform
Get Alerts TNXP Hot Sheet
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 1
Join SI Premium – FREE
Noble Capital analyst Robert LeBoyer initiates coverage on Tonix Pharma (NASDAQ: TNXP) with a Outperform rating and a price target of $0.60.
The analyst commented, "Tonix has developed a pipeline of products in Immunology, CNS, and Infectious Diseases. Several pipeline products are expected to reach clinical milestones or data announcements over the next 12 months, including the Phase 3 RESILIANT trial in fibromyalgia.... TNXP is trading at $0.19 per share with a market capitalization of about $100 million yet its balance sheet on December 31, 2021 had $178.6 million in cash, or about $0.32 per share. This implies no value for its technology and pipeline products. We consider this discount to be below fair value, and see a 2x to 5X cash as a low multiple for early stage biotechnology companies. Our price target is $0.60 per share."
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $0.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Range Resources (RRC) to Sector Perform
- Harley-Davidson (HOG) PT Lowered to $36 at Citi
- Morgan Stanley Upgrades EPAM Systems (EPAM) to Equalweight
Create E-mail Alert Related Categories
Analyst Comments, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!